Less intense chemotherapy more effective and less toxic for patients with advanced Hodgkin's lymphoma

April 3, 2012

A study published Online First by The Lancet has found that patients with advanced Hodgkin's lymphoma (a cancer affecting lymph tissue) can be treated more effectively with lower doses of chemotherapy. The study is by Dr Andreas Engert, University Hospital of Cologne, Germany, and colleagues.

In this , patients were randomised to receive either eight cycles of a standard regimen with radiotherapy or six cycles plus radiotherapy. BEACOPP14 is given in 2-week intervals in contrast to BEACOPPescalated which is given in 3-week intervals. The dose of various drugs is higher in the BEACOPPescalated regimen as compared to the "baseline" version which is used in BEACOPP14. The authors thus evaluated two different approaches to reduce toxicity of chemotherapy in this new study: one approach used 6 cycles of treatment (6xBEACOPP escalated) instead of 8 (the old standard); the other used the lower dose variant (BEACOPP14) given at shorter time intervals.

Of the 2182 patients enrolled in the study, 2126 patients were included in the intention-to-treat analysis set, 705 in the 8× Besc group, 711 in the 6× Besc group, and 710 in the 8×B14 group. Freedom from treatment failure was sequentially non-inferior for the 6× Besc and 8× B14 groups as compared with 8×Besc. 5-year freedom from treatment failure rates were 84% for the 8× Besc group, 89% for 6×Besc group, and 85% for the 8× B14 group. Overall survival in the three groups was 92%, 95%, and 95% respectively, and was significantly better with 6× Besc than with 8×Besc. The 8× Besc group showed a higher mortality (8%) than the 6× Besc (5%) and 8× B14 (5%) groups, mainly due to differences in treatment-related events and secondary cancers.

The authors say: "Treatment with six cycles of BEACOPPescalated followed by PET-guided radiotherapy was more effective in terms of freedom from treatment failure and less toxic than eight cycles of the same chemotherapy regimen. Thus, six cycles of BEACOPPescalated should be the treatment of choice for advanced stage Hodgkin's . PET done after can guide the need for additional in this setting."

They add: "In the HD15 study presented here, we found better overall survival, superior tumour control, and less toxicity with 6 cycles of BEACOPPescalated as compared with eight cycles for treatment of advanced stage Hodgkin's lymphoma. Since the data presented here were generated by a large number of contributing centres from all levels of care, the results of HD15 should help reducing barriers against the use of this effective treatment in advanced stage Hodgkin lymphoma."

In a linked Comment, Dr Olivier Casasnovas, Hôpital le Bocage, Dijon, France, and Dr Bertrand Coiffier, Centre Hospitalier Lyon-Sud, France, say: "Although an important step has been reached towards improvement of the balance of efficacy and with the upfront BEACOPPescalated regimen in patients with advanced Hodgkin's lymphoma, the future will require additional efforts to identify patients needing fewer than six cycles of BEACOPPescalated."

Explore further: More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

More information: www.thelancet.com/journals/lan … (11)61940-5/abstract

Related Stories

More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

November 24, 2011
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years ...

Survival rates increase with chemotherapy alone in patients with limited-stage Hodgkin's lymphoma

December 12, 2011
New research led by the NCIC Clinical Trials Group (CTG) at Queen's University has proven patients with limited stage Hodgkin's lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen ...

Recommended for you

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.